Clinical characteristics of hypertrophic cranial pachymeningitis in granulomatosis with polyangiitis: a retrospective single-center study in China

Table 4 Treatment and outcomes of GPA patients with and without HCP

	GPA with HCP n = 26	GPA without HCP n = 52	p-values
Treatment, [n (%)]
MP pulse	18 (69.2)	18 (34.6)	0.004^*
CYC	26 (100)	49 (94.2)	0.532
Rituximab	8 (30.8)	27 (51.9)	0.077
IVIG	8 (30.8)	6 (11.5)	0.076
Intrathecal injection of methotrexate and dexamethasone	18 (69.2)	0 (0.0)	< 0.001^*
Outcome, [n (%)]
Remission	23 (88.5)	48 (92.3)	0.889
Recurrence	16 (61.5)	23 (44.2)	0.150
Death	0 (0.0)	1 (1.9)	1.000

GPA granulomatosis with polyangiitis, HCP hypertrophic cranial pachymeningitis, GCs glucocorticoids (including high, medium, and low doses), MP methylprednisolone, CYC cyclophosphamide (including all doses), RTX rituximab, IVIG intravenous immunoglobulin
^*p < 0.05

ISSN: 1478-6362